$ABBV · AbbVie Inc.
Latest call · 2026-04-23
The call
Head-to-head · Claude vs the Street vs reality
| Claude | Street | Actual | |
|---|---|---|---|
| EPS | $2.62 | $2.51 | ⏳ pending |
| Revenue | $13.10B | $12.94B | — |
| Direction (1d) | 🟢 UP |
🟢 UP
17B · 9H · 0S
|
— |
| 1d move | +1.5% | — | — |
| 3d move | +2.5% | — | — |
Thesis
The pre-guide already absorbed the Humira-cliff bear case — Skyrizi at $21.5B and Rinvoq at $10.1B run-rates are doing the heavy lifting and only need to maintain 20%+ growth, not accelerate. Stock sits 7% below its long-term moving-average base after Cantor's day-before PT cut, so positioning is short-tilted into a name with a 17/9/0 buy-mix and a $253 average target.
What would flip it
A second FY26 guide cut would confirm the immunology engines aren't filling the cliff fast enough and reset the multiple lower.
The market's narrative
Humira is a melting ice cube ($2.9B/yr run-rate vs the $20B+ peak); Skyrizi + Rinvoq must compound at 20%+ to fill the cliff. The Q1 pre-guide ($2.56-$2.60 vs prior $3.01) already put the bear case in the price.
Where the Street may be wrong
- Pre-guide neutralized the EPS landmine — anything above $2.60 is incremental upside. Skyrizi run-rate now $21.5B/yr, Rinvoq $10.1B/yr; even modest q/q acceleration vs guide implies 22%+ combined growth.
- Average PT $253 vs spot $200 = +26% upside on the consensus model — the technical breakdown (stock 7% below the EMA50/200 cross at $214.53) is washing out positioning before the print, which sets up a positioning-driven pop on a clean number.
- Cantor Fitzgerald cut PT to $240 with bearish 'Q1 won't reinvigorate' framing on April 22 — this is sell-side capitulation, the same setup that historically marks the bottom for ABBV after-cliff narratives (post-Humira-LOE 2023 playbook).
Peer read: JNJ Q1 (April 15) had Stelara erosion in line with consensus + Tremfya growth slightly above — the immunology demand backdrop is fine, which de-risks the Skyrizi/Rinvoq absolute-growth narrative without front-running it.
Reasoning
- Pre-guide-priced-in lesson (STLD post-mortem) cuts the other way here: the company DID pre-guide (so EPS is neutralized), but Skyrizi/Rinvoq run-rate beat IS the positive-skew event the lesson said to scan for. Reaction asymmetry is upward.
- Stock 7% below EMA50/200 cross + Cantor PT cut day-before = positioning is short into the print, not long. Beat-then-cover dynamic.
- Confidence is MEDIUM not HIGH because the Q2 guide is the wildcard — if management trims FY26 again (currently $13.96-$14.16), the stock fades the open pop.
- Buy/Hold/Sell mix 17/9/0 with no Sells = no shoe to drop on a downgrade tape; the worst the Street does is a Hold reiterate.
- Avg PT $253 implies +26%; even half the gap closes on a clean Skyrizi beat = $225 trajectory, supporting the +1.5%/+2.5% reaction profile.
Risks to the call
- FY26 EPS guide cut a second time (below $13.96) — confirms the cliff isn't being filled fast enough and resets the multiple.
- Skyrizi or Rinvoq quarterly growth decelerates below 18% — the bull thesis hinges on sustained 20%+ for both.